This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.
Patient is male and aged >18 years old.
Post-radical prostatectomy (RP): PSA ≥0.2 ng/mL on two consecutive measurements obtained ≥6 weeks after surgery;
Post-radiotherapy (as defined by the ASTRO-Phoenix consensus): PSA rise ≥2 ng/mL above the PSA nadir;
Participants with recurrence after other treatments: PSA rise ≥2 ng/mL above the PSA nadir.
Participants who have previously participated in other interventional clinical trials and are within five physical half-lives, or have received radionuclide agents previously with an interval of less than ten physical half-lives prior to study drug injection.
Participants administered any IV iodinated contrast medium within 24 hours, or any high density oral contrast medium (oral water contrast is acceptable) within 5 days, prior to study drug injection.
Known hypersensitivity to the active ingredient or excipients of the study drug.
Participants not capable of getting PET study , or inability to lay still for the duration of the exam.
Single group
68-Ga-NYM032
Diagnostic testIV injection
PPV
Positive predictive value (PPV)were calculated on a per-patient basis on 68Ga-NYM032 PET/CT for detection of tumor location confirmed by the composite truth standard.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
